Zoetis Inc. (ZTS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $121.11. It has a SharesGrow Score of 71/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ZTS = $130.84 (+8% from the current price, the stock appears fairly valued). Analyst consensus target is ZTS = $144 (+18.8% upside).
Valuation: ZTS trades at a trailing Price-to-Earnings (P/E) of 19.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.53.
Financials: revenue is $9.5B, +5.5%/yr average growth. Net income is $2.7B, growing at +8.2%/yr. Net profit margin is 28.2% (strong). Gross margin is 70.5% (+0.9 pp trend).
Balance sheet: total debt is $9.5B against $3.3B equity (Debt-to-Equity (D/E) ratio 2.85, leveraged). Current ratio is 3.03 (strong liquidity). Debt-to-assets is 61.4%. Total assets: $15.5B.
Analyst outlook: 15 / 30 analysts rate ZTS as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 48/100 (Partial), Growth 65/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 76/100 (Pass), Future 58/100 (Partial), Income 85/100 (Pass).
